Back to Search
Start Over
Biologic treatments in Takayasu's Arteritis: A comparative study of tumor necrosis factor inhibitors and tocilizumab
- Publication Year :
- 2021
- Publisher :
- W B Saunders Co-Elsevier Inc, 2021.
-
Abstract
- Objective: To compare the treatment outcomes of TNF inhibitors and tocilizumab (TCZ) in patients with Takayasu arteritis. Methods: Takayasu arteritis patients who were refractory to conventional immunosuppressive (IS) drugs and received biologic treatment were included in this multicenter retrospective cohort study. Clinical, laboratory and imaging data during follow-up were recorded. Remission, glucocorticoid (GC) sparing effect, drug survival was compared between TNF inhibitor and TCZ treatments. Also, a subgroup matched comparison was performed between groups. Results: One hundred and eleven (F/M: 98/13) patients were enrolled. A total of 173 biologic treatment courses (77 infliximab, 49 TCZ, 33 adalimumab, 9 certolizumab, 3 rituximab, 1 ustekinumab and 1 anakinra) were given. Tocilizumab was chosen in 23 patients and TNF inhibitors were chosen in 88 patients as first line biologic agent. Complete/partial remission rates between TCZ and TNF inhibitors were similar at 3rd month and at the end of the follow-up. GC dose decrease (
- Subjects :
- Double-Blind
medicine.medical_specialty
Efficacy
medicine.medical_treatment
Takayasu's arteritis
Antibodies, Monoclonal, Humanized
Gastroenterology
Factor Therapy
Trial
chemistry.chemical_compound
Tocilizumab
Rheumatology
Drug survival
Internal medicine
Ustekinumab
Adalimumab
medicine
Humans
Retrospective Studies
Biological Products
Anakinra
business.industry
medicine.disease
Infliximab
TNF inhibitor
Management
Treatment Outcome
Anesthesiology and Pain Medicine
chemistry
Tumor Necrosis Factor Inhibitors
Rituximab
business
Biologic treatment
medicine.drug
Takayasu arteritis
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....32583f4cd1f1c4fd273191ac49d7c4c4